Core Insights - Tonix Pharmaceuticals has presented data showing that TONMYA significantly reduces fibromyalgia pain compared to placebo in a Phase 3 study, indicating its potential as an effective non-opioid treatment for this chronic pain disorder [1][2][3]. Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company that markets TONMYA™, the first new prescription medicine approved for fibromyalgia in over 15 years [4]. - The company also has a pipeline focused on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases [5]. Product Details - TONMYA is a sublingual formulation designed for bedtime dosing, which bypasses first-pass metabolism, optimizing drug exposure during sleep and minimizing daytime exposure to its active metabolite [2][3]. - The Phase 3 RESILIENT trial involved 456 participants and demonstrated a statistically significant reduction in weekly average pain scores at Week 14 (p<0.0001) with an effect size of 0.38, along with improvements in sleep disturbance, fatigue, and other fibromyalgia symptoms [2][3]. Market Need - Fibromyalgia affects over 10 million adults in the U.S., and there is a clear demand for effective non-opioid alternatives as current treatments often have tolerability issues and side effects [2][3].